Microbot Medical wins Israeli clearance to market LIBERTY endovascular robotic system

Microbot Medical

Microbot Medical

MBOT

0.00
  • Microbot Medical won Israeli Health Ministry AMAR marketing clearance for its LIBERTY endovascular robotic system, its first approval outside the U.S.
  • The clearance enables commercialization in Israel and supports a Free Sale Certificate for submissions in additional markets.
  • Microbot reiterated it is targeting CE Mark certification by end-2026 to expand into the EU.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260830PRIMZONEFULLFEED9726406) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.